Identification of genetic polymorphisms that are risk factors for neutropenia in TPF therapy

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K18761
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: Tasaki Akihisa 東京医科歯科大学, 東京医科歯科大学病院, 助教 (80737271)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 頭頸部癌 / TPF療法 / 好中球減少症 / ABCB1遺伝子多型

Outline of Final Research Achievements

We investigated the incidence of neutropenia and febrile neutropenia in patients who underwent concurrent chemoradiotherapy with cisplatin, 5-FU, and Docetaaxel (TPF) for head and neck cancer. In addition, genetic analysis was performed on the ABCB1 gene polymorphisms in the target patients, and statistical analysis was performed on the association between the occurrence of neutropenia and febrile neutropenia and the ABCB1 gene polymorphisms.

Free Research Field

頭頸部癌

Academic Significance and Societal Importance of the Research Achievements

TPF療法は好中球減少症など血液毒性が高頻度で発生することは既に知られている。改めて実臨床でのデータを示すとともに、遺伝子多型などの関連が示唆された。
今後もTPF療法を行う際にG-CSF製剤の使用など支持療法が必要であることを示すことができ、安全な患者管理に繋がるとお思われる。